4//SEC Filing
Lewicki John A. 4
Accession 0000899243-19-010987
CIK 0001302573other
Filed
Apr 22, 8:00 PM ET
Accepted
Apr 23, 4:15 PM ET
Size
5.9 KB
Accession
0000899243-19-010987
Insider Transaction Report
Form 4
Lewicki John A.
EVP & Chief Scientific Officer
Transactions
- Disposition from Tender
Common Stock
2019-04-23−142,534→ 0 total
Footnotes (2)
- [F1]On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own.
- [F2](Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock.
Documents
Issuer
OncoMed Pharmaceuticals Inc
CIK 0001302573
Entity typeother
Related Parties
1- filerCIK 0001553352
Filing Metadata
- Form type
- 4
- Filed
- Apr 22, 8:00 PM ET
- Accepted
- Apr 23, 4:15 PM ET
- Size
- 5.9 KB